Event Date: Dec 06, 2018
Alzheimer’s disease is no longer simply a state of dementia. It is a disease that creeps up gradually in the brain for more than 20 years before the earliest symptoms. Diagnosing and treating the disease before it affects one’s mental abilities is paramount. In this Webinar, you will learn about the biomarkers that are shaping our thinking about how we diagnosis Alzheimer’s disease and how we should be approaching treatment opportunities through clinical trials.
This integrated KTE webinar event is brought to you by brainXchange in partnership with the Alzheimer Society of Canada and the Canadian Consortium of Neurodegeneration in Aging (CCNA).
Dr. Sharon Cohen, MD, FRCPC
Dr. Sharon Cohen is a Canadian-trained behavioural neurologist. She is the medical director and site principal investigator at Toronto Memory Program. She is known for her excellence in patient care, teaching and clinical research. She holds an FRCPC in neurology from the Royal College of Physicians and Surgeons of Canada.
For the past 25 years, Dr. Cohen has been committed to improving treatment for Alzheimer’s and related disorders. Her memory clinic and research site are among the most active in Canada and have provided care and clinical trial opportunities to thousands of individuals.
Her research is focused on pharmacologic advances and her site has been repeatedly credited as the “go to” centre for clinical trials in Canada. Toronto Memory Program holds the distinction of being a site within the Global Alzheimer’s Platform and was recently awarded for superior performance and quality in clinical research. Dr. Cohen has represented Canada on numerous international research advisory boards and steering committees.
Despite holding academic and hospital appointments, Dr. Cohen chooses to practice in the community, in keeping with her belief that dementia care and clinical research are best offered in the real world setting.
Dr. Cohen is a frequent lecturer and contributes to various media events including those on medical ethics. She is known for her advocacy of individuals with neurodegenerative diseases.